NCT06283719View on ClinicalTrials.gov

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Small Cell Lung CancerNeuroendocrine Cancer
Interventions
BIOLOGICAL

ZG006

ZG006 will be administered as an intravenous (IV) infusion.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY